Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
ACAPODENE®and, ACAPODENE®in, ACAPODENE®or, ACAPODENE®within, Adult, Advair, AFUD, agonist, ANDA, bachelor, back, baseline, Baylor, beta, Brady, capacity, cardioprotective, chemoprevention, Chilcott, Christopher, colorectal, Columbia, consecutive, Conzen, culmination, deadline, Deficiency, deliverable, Dentistry, Dermatology, description, dollar, dual, Duke, durable, embolism, entirety, ESS, extremity, FARESTON®to, fellowship, femur, Fixed, foregoing, Fuqua, GAAP, guaranteed, Hesselberg, Houston, immobilization, Immunex, induced, inflammation, installment, Investmentsin, Jeff, Jeffrey, Jersey, Jr, Lambert, Landlord, lessor, leukemia, Likewise, lung, lymphocytic, lymphoma, mentioned, mild, Military, monthly, Morton, NAV, nonfinancial, nonrefundable, ocular, orderly, OstarineTMand, OstarineTMdrug, OstarineTMfor, plc, pooled, postdoctoral, prespecified, proper, Puget, purport, radiograph, reclassification, recurring, reevaluated, Ronald, Scholar, Sound, South, steering, subset, substance, substantive, suitable, SUSA, tadalafil, tenant, thereunder, tiered, tone, tool, Translational, unclear, undelivered, unrealized, upward, Valtrex, VTE, Warner, Wood
Removed:
Abbott, achieving, Advisor, amend, Amherst, amortize, andromustine, area, Asian, ATAC, Biochemistry, Biomed, Bird, Boger, CellCeptTransplant, ChemSyn, Children, component, construction, continuously, creating, culture, Deputy, direction, discounted, EaglePicher, eventually, expert, extending, fellow, forma, GCP, gene, Harvard, identifying, Immunology, Invertebrate, involvement, IPO, Jude, Karen, kill, kind, Leader, Mayo, median, midpoint, Mississippi, negotiating, nephrology, obstruction, poor, pro, prostarine, Quotation, refractory, reimbursed, remission, Renin, Roche, Science, Scientist, shortened, shrink, St, stage, studying, superseded, tract, Transplantation, undiscounted, unsuccessful, unvested, urinary, Venture, Veverka, viral, Zoology
Filing tables
Filing exhibits
- 10-K Annual report
- 10.43 EX-10.43 Exclusive License and Collaboration Agreement
- 10.44 EX-10.44 2008 Compensation Information for Registrant's Executive Officers
- 10.45 EX-10.45 Non-employee Director Compensation Arrangements
- 10.46 EX-10.46 Sublease Agreement
- 12.1 EX-12.1 Statement of Compensation of Deficiency of Earnings Available to Cover Fixed Charges
- 23.1 EX-23.1 Consent of Independent Registered Public Accounting Firm
- 31.1 EX-31.1 Section 302 Certification of the CEO
- 31.2 EX-31.2 Section 302 Certification of the CFO
- 32.1 EX-32.1 Section 906 Certification of the CEO
- 32.2 EX-32.2 Section 906 Certification of the CFO
Related press release
ONCT similar filings
Filing view
External links
Exhibit 12.1
GTx, Inc.
Computation of Deficiency of Earnings Available to Cover Fixed Charges
Computation of Deficiency of Earnings Available to Cover Fixed Charges
Year Ended December 31, | ||||||||||||||||||||
2007 | 2006 | 2005 | 2004 | 2003 | ||||||||||||||||
Loss: | ||||||||||||||||||||
Pretax loss from continuing operations | $ | (40,359 | ) | $ | (35,510 | ) | $ | (36,839 | ) | $ | (22,348 | ) | $ | (14,194 | ) | |||||
Fixed charges (from below) | 35 | 32 | 32 | 21 | 18 | |||||||||||||||
Total loss | $ | (40,324 | ) | $ | (35,478 | ) | $ | (36,807 | ) | $ | (22,327 | ) | $ | (14,176 | ) | |||||
Fixed charges: | ||||||||||||||||||||
Estimated interest portion of rent expenses | $ | 35 | $ | 32 | $ | 32 | $ | 21 | $ | 18 | ||||||||||
Total fixed charges | $ | 35 | $ | 32 | $ | 32 | $ | 21 | $ | 18 | ||||||||||
Coverage deficiency | $ | (40,359 | ) | $ | (35,510 | ) | $ | (36,839 | ) | $ | (22,348 | ) | $ | (14,194 | ) | |||||